Antimüllerian hormone as predictor of reproductive outcome in subfertile women with elevated basal follicle-stimulating hormone levels: a follow-up study

In a prospective cohort study in subfertile women with elevated basal FSH levels, AMH is identified as a marker for actual fertility.


Felicia Yarde, M.D., Marlies Voorhuis, M.D., Madeleine Dólleman, M.D., Erik A.H. Knauff, M.D., Ph.D., Marinus J.C. Eijkemans, M.Sc., Frank J.M. Broekmans, M.D., Ph.D.

Volume 100, Issue 3, Pages 831-838.e2, September 2013



To investigate the role of serum antimüllerian hormone (AMH) as a predictor of live birth and reproductive stage in subfertile women with elevated basal FSH levels.


A prospective observational cohort study conducted between February 2005 and June 2009.


Tertiary fertility center.


Subfertile women with [1] a regular menstrual cycle (mean cycle length 25–35 days); [2] basal FSH concentrations ≥12.3 IU/L; and [3] younger than 40 years (n = 96).



Main Outcome Measure(s):

Live birth and reproductive stage according to the Stages of Reproductive Aging Workshop.


A cumulative live birth rate of 63.5% was observed during a median follow-up of 3.3 years (n = 85). The AMH level was significantly associated with live birth. There was evidence of a nonlinear prediction pattern, with an increase in chances of live birth until an AMH level of 1 μg/L. Other ovarian reserve tests and chronological age appeared of limited value in predicting live birth. In addition, AMH was significantly associated with the timing of reproductive stages (n = 68) (i.e., the occurrence of menopausal transition or menopause during follow-up).


The present findings suggest applicability of AMH determination as a marker for actual fertility in subfertile women with elevated basal FSH levels.

Read the full text at:

Please sign in or register for FREE

Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.